About Allterum
Allterum is a company based in Houston (United States) founded in 2018.. Allterum has raised $65.8 million across 3 funding rounds from investors including Orbimed, Arjun Goyal and Nextech Invest. Allterum offers products and services including CD127 Monoclonal Antibody. Allterum operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Houston, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Allterum Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$65.8 M (USD)
in 3 rounds
-
Latest Funding Round
$64 M (USD), Series A
Jan 20, 2022
-
Investors
Orbimed
& 5 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Allterum
Allterum offers a comprehensive portfolio of products and services, including CD127 Monoclonal Antibody. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets CD127 for treating hematologic malignancies and solid tumors.
Unlock access to complete
Funding Insights of Allterum
Allterum has successfully raised a total of $65.8M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $64 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $64.0M
-
First Round
First Round
(21 Apr 2020)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2022 | Amount | Series A - Allterum | Valuation | Orbimed , Nextech Invest | |
| Dec, 2020 | Amount | Seed - Allterum | Valuation | Fannin Innovation Studio |
|
| Apr, 2020 | Amount | Grant - Allterum | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Allterum
Allterum has secured backing from 6 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Orbimed, Arjun Goyal and Nextech Invest. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Allterum
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Allterum
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Allterum Comparisons
Competitors of Allterum
Allterum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| domain | founded_year | HQ Location |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Allterum
Frequently Asked Questions about Allterum
When was Allterum founded?
Allterum was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Allterum located?
Allterum is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Is Allterum a funded company?
Allterum is a funded company, having raised a total of $65.8M across 3 funding rounds to date. The company's 1st funding round was a Grant of $2.9M, raised on Apr 21, 2020.
What does Allterum do?
Allterum was founded in 2018 in Houston, United States, within the biotechnology sector. Focus is placed on developing drugs for leukemia treatment, particularly monoclonal antibody therapies targeting pediatric acute lymphoblastic leukemia. Additional efforts involve identifying T-cell origin cancers to enable precise patient treatment. Operations center on oncology research and therapeutic innovation for hematologic malignancies.
Who are the top competitors of Allterum?
Allterum's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
What products or services does Allterum offer?
Allterum offers CD127 Monoclonal Antibody.
Who are Allterum's investors?
Allterum has 6 investors. Key investors include Orbimed, Arjun Goyal, Nextech Invest, Boxer Capital, and Fannin.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.